Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | FURIN | P09958 | 3/20 | 0.31 |
| ▸ | NPY1R | P25929 | 2/20 | 0.31 |
| ▸ | NPY4R | P50391 | 2/20 | 0.31 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17722918 | 0.93 | GLP1R (0.33) | C3AR1NPY1RNPY4ROPRK1FAP | |
| SCHEMBL13805702 | 0.93 | FURIN (0.32) | C3AR1POLBHSD17B10FURINNPY1R | |
| SCHEMBL13311280 | 0.91 | POLB (0.33) | POLBHSD17B10 | |
| SCHEMBL13310984 | 0.88 | FAP (0.36) | FURINNPY1RNPY4ROPRK1FAP | |
| SCHEMBL17841870 | 0.87 | GLP1R (0.40) | C3AR1POLBFURINNPY1RFAP | |
| SCHEMBL20263703 | 0.87 | GLP1R (0.40) | C3AR1POLBFURINNPY1RFAP | |
| SCHEMBL20263702 | 0.87 | GLP1R (0.40) | C3AR1POLBFURINNPY1RFAP | |
| SCHEMBL22841031 | 0.87 | GLP1R (0.33) | C3AR1POLBHSD17B10NPY1RNPY4R | |
| SCHEMBL22115954 | 0.87 | GLP1R (0.40) | C3AR1POLBFURINNPY1RFAP | |
| SCHEMBL17842470 | 0.87 | GLP1R (0.40) | C3AR1POLBFURINNPY1RFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090162372-A1 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE | MEDAREX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162372-A1 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE | MEDAREX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162372-A1 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE | FN1, EDNRB, EDF1 | C3AR1 153/4885POLB 3600/4885HSD17B10 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.